arrow
Y

Yuee Teng

China Medical University
H指数:31
被引数:2,754

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial

fruroliparib 联合或不联合 apatinib 治疗 HER2 阴性转移性乳腺癌携带胚系 BRCA1/2 突变患者(FABULOUS):一项多中心、三臂、开放标签、随机、III 期试验的期中分析

2025-11-240
PRE
Safety and tolerability of bireociclib for the treatment of advanced solid tumors as monotherapy and in combination with endocrine therapy: a multicenter, open-label, phase 1 clinical trial

比卡鲁胺单药治疗及联合内分泌疗法治疗晚期实体瘤的安全性和耐受性:一项多中心、开放标签、I期临床试验

2025-10-100
OAAI
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer
2024-12-040
OAAI
Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study
2024-09-022
OAAI
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial

Toripalimab联合nab-紫杉醇治疗转移性或复发性三阴性乳腺癌: 一项随机3期试验

2024-01-0827
PRE
Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition)
2023-12-011
OAAI
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial

Pyrotinib与安慰剂联合曲妥珠单抗和多西他赛作为HER2阳性转移性乳腺癌患者的一线治疗 (PHILA): 随机,双盲,多中心,3期试验

2023-10-3134
OAAI
Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial

Pyrotinib联合卡培他滨治疗曲妥珠单抗耐药的HER2-positive晚期乳腺癌 (图片): 一项单臂多中心2期试验

2023-08-0911
OAAI
Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive/human epidermal growth factor receptor 2-advanced breast cancer (FRIEND study)

氟维司坦与依西美坦一线治疗中国绝经后雌激素受体阳性/人表皮生长因子受体2-晚期乳腺癌的临床疗效 (FRIEND研究)

2023-05-018
PRE
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

Dalpiciclib或安慰剂联合氟维司群治疗激素受体阳性和HER2-negative晚期乳腺癌: 一项随机3期试验

2021-11-0489
OA